NO312681B1 - Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet - Google Patents
Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet Download PDFInfo
- Publication number
- NO312681B1 NO312681B1 NO19912665A NO912665A NO312681B1 NO 312681 B1 NO312681 B1 NO 312681B1 NO 19912665 A NO19912665 A NO 19912665A NO 912665 A NO912665 A NO 912665A NO 312681 B1 NO312681 B1 NO 312681B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- wild
- type
- mutated
- gene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title claims description 23
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108700025694 p53 Genes Proteins 0.000 claims abstract description 18
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 abstract description 21
- 230000001629 suppression Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 110
- 108700028369 Alleles Proteins 0.000 description 25
- 230000035772 mutation Effects 0.000 description 24
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 23
- 241000700605 Viruses Species 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 230000012010 growth Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 241001529936 Murinae Species 0.000 description 12
- 201000008968 osteosarcoma Diseases 0.000 description 12
- 208000005623 Carcinogenesis Diseases 0.000 description 10
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 10
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 10
- 230000036952 cancer formation Effects 0.000 description 10
- 231100000504 carcinogenesis Toxicity 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000005757 colony formation Effects 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 201000000582 Retinoblastoma Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 108050002653 Retinoblastoma protein Proteins 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 201000005296 lung carcinoma Diseases 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000001037 lung lymphoma Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010573 double replacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150020201 RB gene Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000012978 nondisjunction Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000031267 regulation of DNA replication Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57340590A | 1990-08-24 | 1990-08-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912665D0 NO912665D0 (no) | 1991-07-08 |
| NO912665L NO912665L (no) | 1992-02-25 |
| NO312681B1 true NO312681B1 (no) | 2002-06-17 |
Family
ID=24291866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19912665A NO312681B1 (no) | 1990-08-24 | 1991-07-08 | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0710722A1 (de) |
| JP (1) | JP2838090B2 (de) |
| KR (1) | KR970000189B1 (de) |
| AT (1) | ATE136793T1 (de) |
| AU (3) | AU653356B2 (de) |
| CA (1) | CA2047090C (de) |
| DE (1) | DE69118789T2 (de) |
| DK (1) | DK0475623T3 (de) |
| ES (1) | ES2085966T3 (de) |
| FI (1) | FI105014B (de) |
| NO (1) | NO312681B1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20010427A1 (en) * | 1990-04-10 | 2003-03-05 | Canji Inc | Gene therapy for cell proliferative diseases |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| CA2108144A1 (en) | 1991-03-06 | 1992-09-07 | Jack A. Roth | Methods and compositions for the selective inhibition of gene expression |
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| EP0643726B1 (de) * | 1992-05-26 | 1999-08-18 | Rijksuniversiteit te Leiden | Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten |
| CA2144848A1 (en) * | 1992-09-18 | 1994-03-31 | H. Michael Shepard | Gene therapy by retroviral vector with tumor suppressive gene |
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| CA2086577A1 (en) * | 1992-12-31 | 1994-07-01 | Rick E. Preddie | Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene |
| IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
| US6160106A (en) * | 1993-10-12 | 2000-12-12 | Yeda Research & Development Co., Ltd. | Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins |
| WO1995011301A1 (en) * | 1993-10-19 | 1995-04-27 | The Regents Of The University Of Michigan | P53-mediated apoptosis |
| FR2712602B1 (fr) * | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
| US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
| US5721340A (en) * | 1994-11-28 | 1998-02-24 | The Wistar Institute Of Anatomy & Biology | p53 proteins with altered tetramerization domains |
| DE69637147T2 (de) | 1995-07-28 | 2008-03-06 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
| GB9519299D0 (en) | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
| GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| US5847083A (en) * | 1996-08-21 | 1998-12-08 | The Wistar Institute Of Anatomy And Biology | Modified p53 constructs which enhance DNA binding |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6656480B2 (en) | 1996-01-11 | 2003-12-02 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| US6861506B1 (en) | 1996-01-11 | 2005-03-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| GB9606961D0 (en) * | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
| US8551970B2 (en) | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
| US5876972A (en) * | 1996-09-23 | 1999-03-02 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| EP0968284B1 (de) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
| US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
| CA2214461A1 (en) | 1997-09-02 | 1999-03-02 | Mcgill University | Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53 |
| AU3208699A (en) | 1998-03-27 | 1999-10-18 | Johns Hopkins University, The | P40 protein acts as an oncogene |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| AU2005276231A1 (en) | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases |
| AU2005305347A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362623A (en) * | 1991-06-14 | 1994-11-08 | The John Hopkins University | Sequence specific DNA binding by p53 |
| IE20010427A1 (en) * | 1990-04-10 | 2003-03-05 | Canji Inc | Gene therapy for cell proliferative diseases |
| DE69133528T2 (de) * | 1990-06-27 | 2006-09-07 | Princeton University | Proteinkomplex p53/p90 |
-
1991
- 1991-07-08 NO NO19912665A patent/NO312681B1/no not_active IP Right Cessation
- 1991-07-15 CA CA002047090A patent/CA2047090C/en not_active Expired - Fee Related
- 1991-08-20 JP JP3232371A patent/JP2838090B2/ja not_active Expired - Fee Related
- 1991-08-20 AU AU82629/91A patent/AU653356B2/en not_active Ceased
- 1991-08-22 KR KR91014477A patent/KR970000189B1/ko not_active IP Right Cessation
- 1991-08-23 EP EP95114723A patent/EP0710722A1/de not_active Withdrawn
- 1991-08-23 FI FI913978A patent/FI105014B/fi not_active IP Right Cessation
- 1991-08-23 DK DK91307791.3T patent/DK0475623T3/da active
- 1991-08-23 ES ES91307791T patent/ES2085966T3/es not_active Expired - Lifetime
- 1991-08-23 DE DE69118789T patent/DE69118789T2/de not_active Revoked
- 1991-08-23 EP EP91307791A patent/EP0475623B1/de not_active Revoked
- 1991-08-23 AT AT91307791T patent/ATE136793T1/de not_active IP Right Cessation
-
1994
- 1994-12-29 AU AU81836/94A patent/AU8183694A/en not_active Abandoned
-
1997
- 1997-12-09 AU AU47651/97A patent/AU4765197A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69118789T2 (de) | 1996-09-26 |
| KR970000189B1 (en) | 1997-01-06 |
| CA2047090C (en) | 1998-08-04 |
| FI105014B (fi) | 2000-05-31 |
| NO912665D0 (no) | 1991-07-08 |
| AU653356B2 (en) | 1994-09-29 |
| EP0710722A1 (de) | 1996-05-08 |
| FI913978A (fi) | 1992-02-25 |
| NO912665L (no) | 1992-02-25 |
| AU4765197A (en) | 1998-03-26 |
| EP0475623B1 (de) | 1996-04-17 |
| DK0475623T3 (da) | 1996-05-13 |
| JP2838090B2 (ja) | 1998-12-16 |
| EP0475623A1 (de) | 1992-03-18 |
| DE69118789D1 (de) | 1996-05-23 |
| ES2085966T3 (es) | 1996-06-16 |
| JPH0759579A (ja) | 1995-03-07 |
| ATE136793T1 (de) | 1996-05-15 |
| AU8183694A (en) | 1995-02-23 |
| FI913978A0 (fi) | 1991-08-23 |
| AU8262991A (en) | 1992-02-27 |
| CA2047090A1 (en) | 1992-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312681B1 (no) | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet | |
| US5532220A (en) | Genetic mechanisms of tumor suppression | |
| Toguchida et al. | Mutation spectrum of the p53 gene in bone and soft tissue sarcomas | |
| Cheng et al. | Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines | |
| Shirakata et al. | The× gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells | |
| Yoshida et al. | Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells | |
| Haase et al. | The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms | |
| Justice IV et al. | The MET gene is a common integration target in avian leukosis virus subgroup J-induced chicken hemangiomas | |
| Dudley et al. | What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas | |
| JPH03500245A (ja) | ヒト赤血球特異的転写エンハンサー | |
| Mori et al. | Mutations of the p53 tumour suppressor gene in haematologic neoplasms | |
| Roth | Molecular events in lung cancer | |
| Ramakrishnan et al. | Abl genes | |
| JP2000512129A (ja) | ブタレトロウィルス | |
| DE69830596T2 (de) | Ein tumorsuppressor namens ts10q23.3 | |
| WO2010151827A1 (en) | X-box binding proteins (xbp-1) variants and methods of using the same | |
| Ramalakshmi et al. | Cancer and oncogenes-An Overview | |
| JPH09508267A (ja) | 自然抵抗性結合マクロファージタンパク質およびその使用法 | |
| JP2005500835A (ja) | Ｐｅｒｖスクリーニング法およびその使用 | |
| AU5659300A (en) | Genetic mechanisms of tumour suppression | |
| Roth | Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment | |
| US20230313235A1 (en) | Compositions for use in treating autosomal dominant best1-related retinopathies | |
| US20220002714A1 (en) | Crispr system for genome editing | |
| Roebroek | Genetic organization of the human and feline c-fes/fps proto-oncogenes | |
| Tai | The genetic penetrance ofneu in rat mammary glands in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |